Physician

Joseph My, D.O.

According to 2025 Medicare claims, Joseph My, D.O. (NPI: 1174720734) practices hematology/oncology in the Port St. Lucie, FL market, with the plurality of this provider's patient population coming from St. Lucie, FL. This provider's primary affiliated billing organization is STUART ONCOLOGY ASSOCIATES, PA (NPI: 1902858822; TIN: 592003116) and primary practice location at 34987-4423.

My's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 739 traditional Medicare patients, billed 363,801 HCPCS/CPT codes, and received $4,342,337 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,854 prescription claims across 402 beneficiaries totaling $10,413,646 in drug costs, led by Xtandi (Enzalutamide). DME data shows 64 claims. Open Payments data shows 185 records totaling $3,960. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $338,646 to $4,342,337. Similarly, Part D prescription costs have moved sharply higher in recent years, from $288,747 to $10,413,646. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	190	28,469	$338,646
2019	548	195,195	$2,314,887
2020	507	229,375	$2,785,831
2021	581	220,635	$3,700,158
2022	710	182,832	$3,652,652
2023	770	196,055	$4,238,358
2024	739	363,801	$4,342,337

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	83	213	$288,747
2019	213	1,274	$1,980,900
2020	244	1,372	$2,391,977
2021	267	1,505	$3,413,955
2022	289	1,747	$4,495,691
2023	318	1,972	$5,382,862
2024	402	2,854	$10,413,646

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	44	$3,461
2020	N/R	11	$1,553
2021	N/R	N/R	N/R
2022	N/R	64	$1,662
2023	N/R	103	$9,912
2024	N/R	64	$1,590

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	428	1,299	$99
82728	Ferritin (blood protein) level	191	377	$13
80053	Blood test, comprehensive group of blood chemicals	390	1,366	$10
36415	Insertion of needle into vein for collection of blood sample	470	1,918	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	529	2,954	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xtandi	Enzalutamide	58	1,740	$783,086
Lenalidomide	Lenalidomide	55	1,365	$696,080
Cabometyx	Cabozantinib S-Malate	22	810	$677,749
Revlimid	Lenalidomide	34	910	$561,241
Pomalyst	Pomalidomide	22	616	$491,352

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	18	$768
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	18	$339
A4357	Bedside drainage bag, day or night, with or without anti-reflux device, with or without tube, each	N	N/R	13	$270
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	15	$213

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	185	$3,960	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Joseph My, D.O.?

Tedicare shows public-source Medicare data for Joseph My, D.O. (NPI 1174720734), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Joseph My, D.O. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Joseph My, D.O.?

Joseph My, D.O. is linked to STUART ONCOLOGY ASSOCIATES, PA (billing NPI 1902858822) in the available physician profile data.

Does Joseph My, D.O. have Open Payments data?

Joseph My, D.O. has 185 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.